KOSDAQBiotech & Pharma018680

Seoul Pharma

₩1,646▼ 2.89%2026-11-18 close
Market Cap
₩19.2B
Turnover
₩10,326,208
Volume
6.3K
Shares out.
11.7M
PER
—
PBR
0.5×
EPS
-₩189
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Operating Losses Persist as Revenue Keeps Declining

Seoul Pharma swung to an operating loss in 2025, and both the operating loss and the revenue decline have continued through the third quarter of 2026, with the 2026 annual report as the next checkpoint.

  1. 1

    The company posted an operating loss of KRW 1.28 billion in 2025 after an operating profit of KRW 1.53 billion in 2024, a swing into the red.

  2. 2

    Third-quarter 2026 revenue fell 22.9% year on year to KRW 10.5 billion, while the operating loss widened to KRW 973 million.

  3. 3

    Over the last four quarters (Q4 2025 to Q3 2026), the controlling-shareholder net loss totaled KRW 2.21 billion.

  4. 4

    Total equity at the end of 2025 was KRW 41 billion and the debt ratio was 74.8%, with book equity larger than the market capitalization.

  5. 5

    The cost of sales ratio was 38.5% and the SG&A ratio was 58.6% in 2024, and rising cost burdens were cited as a factor behind weaker profitability in the first half of 2025.

02

Business structure

Seoul Pharma was founded in 1985, manages pharmaceutical manufacturing and sales as its core business, and listed on KOSDAQ in 2000. The company is known as a specialist in orally disintegrating film (ODF) formulations.

In 2024, non-tablet products made up 74.32% of sales, followed by hard capsules at 13.42%, liquid formulations at 5.59%, and soft capsules at 3.19%. Non-tablet merchandise accounted for 2.79%, ointments and creams for 1.28%, and other sales for 0.76% in the same year.

Domestic sales were 97.7% of the 2024 total, with exports at 2.3%, so the business is centered on Korea. Media reports said seven key OTC products have recorded modest annual sales of roughly KRW 300 million to KRW 400 million over the past five years, limiting their contribution to total revenue.

The head office and production base is in Osong, Cheongju, Chungbuk. Compared with large biopharma names, the portfolio is built around formulation-based products rather than biologics. Segment-level revenue and product-level prescription trends are shown only in the 2024 composition.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩13.6B-₩33,603,519−0.2%
2025Q4₩13.6B-₩200M−1.6%
2026Q1₩12.1B-₩200M−1.5%
2026Q2₩11.8B-₩300M−2.9%
2026Q3₩10.5B-₩1B−9.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩50.1B₩1.7B₩900M3.5%2.4%76.2%
2023₩52.5B₩1.2B₩3.5B2.3%9.1%64.2%
2024₩53.6B₩1.5B₩1.7B2.9%4.2%78.3%
2025₩52.1B-₩1.3B₩800M−2.5%1.8%74.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

On a disclosed basis, revenue rose from KRW 50.1 billion in 2022 to KRW 52.5 billion in 2023 (up 4.8% year on year) and KRW 53.6 billion in 2024 (up 2.1%), then fell to KRW 52.1 billion in 2025 (down 2.7%). Over 2022 to 2025, 2024 was the largest year and 2022 the smallest.

Operating profit went from KRW 1.74 billion in 2022 to KRW 1.21 billion in 2023 (down 30.2%) and KRW 1.53 billion in 2024 (up 26.0%), and then turned into an operating loss of KRW 1.28 billion in 2025, a swing into the red. The operating margin was 3.5% in 2022, 2.3% in 2023, and 2.9% in 2024, and then -2.5% in 2025.

The company attributed the main cause of the 2025 swing to a temporary rise in management rationalization costs tied to a business restructuring.

Net income attributable to controlling shareholders rose from KRW 855 million in 2022 to KRW 3.52 billion in 2023 (up 311.3%), the peak, and then fell to KRW 1.7 billion in 2024 (down 51.7%) and KRW 754 million in 2025 (down 55.6%), declining for two consecutive years.

In 2023, operating profit fell while controlling-shareholder net income rose sharply, which suggests that non-operating items had a large effect. Net income in this period was disclosed at the same amounts as controlling-shareholder net income, so no gap between the two appears.

Quarterly revenue has declined for four consecutive quarters from Q4 2025 to Q3 2026, moving from KRW 13.6 billion to KRW 12.1 billion, KRW 11.8 billion, and KRW 10.5 billion, and Q3 2026 was down 22.9% year on year.

Operating losses ran from KRW 33.6 million in Q3 2025 to KRW 217 million in Q4 2025, KRW 186 million in Q1 2026, KRW 343 million in Q2 2026, and KRW 973 million in Q3 2026, five consecutive quarters in the red, with the Q3 2026 loss the largest of the period.

Controlling-shareholder net income was KRW 2.62 billion in Q3 2025, then turned to a net loss of KRW 376 million in Q4 2025 and continued in the red through Q3 2026, with a net loss of KRW 1.32 billion in that quarter, four consecutive quarters of losses totaling KRW 2.21 billion.

The 2024 cost of sales ratio was 38.5% and the SG&A ratio was 58.6%, and a securities information service attributed weaker profitability in the first half of 2025 to higher cost burdens.

05

Industry analysis

Results in the pharmaceutical sector show a clear gap between large companies and smaller ones.

According to a preliminary analysis based on Financial Supervisory Service data, the top 10 pharmaceutical companies posted combined third-quarter 2026 revenue of KRW 37.8 trillion, up 2.63% year on year, and operating profit of KRW 331.3 billion, up 11.20%.

A separate analysis of 75 listed pharma and bio companies in the first half of 2026 found that 45 posted operating profits, and it described profits as concentrated in large, high-margin companies.

Against that backdrop, Seoul Pharma's third-quarter 2026 revenue decline and widening operating loss moved in the opposite direction. Non-tablet products, built on formulation technology, account for the largest share of sales, while reports indicate OTC products have contributed little over the past five years.

Domestic sales were 97.7% of the 2024 total, so the company is directly exposed to changes in Korean prescription and distribution conditions. Industry-level indicators are limited for judging the cycle position, so the company's own cost structure and product sales trends are the more reliable reference points.

Direct comparison with top-tier biotech names is limited because scale and business models differ. As the share of profitable companies rises across the sector, Seoul Pharma's task comes down to how it reshapes its cost of sales and SG&A structure.

06

Outlook

The company's disclosed results through the third quarter of 2026 show revenue declining while operating losses widen. At the regular shareholders' meeting held on March 27, 2026, all agenda items, including approval of the 40th fiscal year financial statements and director appointments, passed.

The company attributed the 2025 swing into the red to a temporary rise in management rationalization costs linked to a business restructuring.

Quarterly operating losses have nonetheless increased to KRW 186 million, KRW 343 million, and KRW 973 million in the first three quarters of 2026, so temporary costs alone do not explain the trend.

The FY2025 annual results were disclosed on February 6, 2026, so the FY2026 preliminary annual figures would be expected around early February 2027 if the prior-year timing holds. The 2026 annual business report, the next regular filing, must be submitted by the end of March 2027.

The Q1 2027 quarterly report is due by May 15, 2027. On revenue, the key question is whether the four-quarter decline continues after 2027 Q1. On margins, the question is whether the loss narrows from the -2.5% operating margin of 2025 and whether the cost restructuring shows up in results.

Given the domestic-focused sales mix, recovery in the OTC segment is also a variable that will shape the top-line trend.

07

Valuation

PER
—
PBR
0.5×
ROE
-5.5%
EPS
-₩189
BPS
₩3,382
Dividend per share
₩0

The price-to-book ratio sits below 1x, meaning the market capitalization is smaller than book equity on the balance sheet. Total equity at the end of 2025 was KRW 41 billion, all attributable to controlling shareholders, and total liabilities were KRW 30.7 billion.

In contrast, the company has posted net losses over the last four quarters, so a price-to-earnings ratio cannot be calculated. Cash returns to shareholders through dividends are effectively negligible, so dividends offer little basis for comparison.

Controlling-shareholder net income has declined for two consecutive years since its 2023 peak, and quarterly losses have continued since 2025, which limits earnings-based comparisons. Earnings-based metrics will only carry meaning once the company returns from losses to profits.

A factual starting point for valuation is therefore to view asset value and the earnings recovery side by side. The core of reading this stock is that the asset-based and earnings-based comparisons point in different directions.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Share price below book value

Total equity at the end of 2025 was KRW 41 billion, all attributable to controlling shareholders. The price-to-book ratio sits below 1x, so book assets are larger than the market capitalization. Bulls see this asset base as a cushion against downside in the share price. The debt ratio was 74.8% in 2025, moving between 64.2% in 2023 and 78.3% in 2024.

Record of earnings recovery

Operating profit recovered to KRW 1.53 billion in 2024, up 26.0%, partly reversing the 2023 decline. Controlling-shareholder net income rose 311.3% to KRW 3.52 billion in 2023 from KRW 855 million in 2022. The company's past swings back into profit suggest room for earnings recovery if the business normalizes.

Possible fading of one-off costs

The company attributed the 2025 swing into the red to a temporary rise in rationalization costs from its business restructuring. If these costs are one-time, operating margin could recover toward the 2.9% level of 2024 as restructuring effects show up in SG&A. The 2025 operating margin was -2.5%.

09

Bear factors

Four straight quarters of revenue decline

Revenue fell for four consecutive quarters from Q4 2025 through Q3 2026, and Q3 2026 revenue of KRW 10.5 billion was down 22.9% year on year. Annual revenue fell 2.7% to KRW 52.1 billion in 2025 from KRW 53.6 billion in 2024, extending the downtrend. A shrinking top line raises the burden of fixed costs, which can widen operating losses.

Widening operating loss and net losses

Operating losses have run for five consecutive quarters since Q3 2025, and the Q3 2026 loss of KRW 973 million was the largest of the period. Controlling-shareholder net income swung from a profit in Q3 2025 to a net loss of KRW 1.32 billion in Q3 2026. The four-quarter controlling-shareholder net loss totaled KRW 2.21 billion.

Domestic concentration and weak OTC sales

Domestic sales made up 97.7% of the 2024 total, so the company depends heavily on the Korean market. Non-tablet products accounted for 74.32% of sales, leaving the product mix concentrated. Media reports say OTC products have recorded only KRW 300 million to KRW 400 million a year over the past five years. Higher cost burdens were cited as a factor behind weaker profitability in the first half of 2025.

10

Risk factors

Continued earnings deterioration

If operating and net losses persist across several quarters, cumulative losses could erode total equity over time. Equity was KRW 41 billion at the end of 2025, a sizable base, but the four-quarter controlling-shareholder net loss totaled KRW 2.21 billion. Whether the widening loss trend continues remains the key variable.

Financial structure and cash flow volatility

Total liabilities stood at KRW 30.7 billion at the end of 2025, with a debt ratio of 74.8%. Operating cash flow swung from -KRW 78.21 million in 2022 to KRW 5.26 billion in 2023, -KRW 3.01 billion in 2024, and KRW 1.89 billion in 2025. Given these swings, borrowing capacity and working capital needs remain important variables.

Small-cap profile and domestic product concentration

As a small-cap stock, the share price can be volatile and move sharply with trading conditions. Most sales come from Korea, so the company is directly exposed to domestic prescription, distribution, and policy changes.

Non-tablet products make up a large share of sales, so a shift in a single product can move total revenue noticeably.

11

What to watch next

  1. Early February 2027

    The FY2026 preliminary annual results, showing how far the four-quarter revenue decline carried into the full year and whether the operating loss grew beyond the KRW 1.28 billion of 2025. The FY2025 preliminary disclosure was made on February 6, 2026.

  2. By March 31, 2027

    The deadline for the 2026 annual business report. The operating margin's recovery from -2.5% in 2025 is the key item, alongside the regular shareholders' meeting agenda. The prior-year meeting was held on March 27, 2026.

  3. By May 15, 2027

    The deadline for the Q1 2027 quarterly report. The checkpoints are whether revenue stops falling from the KRW 10.5 billion level of Q3 2026 and whether the operating loss narrows from KRW 973 million.

12

Overall view

Seoul Pharma swung to an operating loss of KRW 1.28 billion in 2025 and has continued to post operating and net losses through the third quarter of 2026. Revenue peaked at KRW 53.6 billion in 2024, fell to KRW 52.1 billion in 2025, and declined for four consecutive quarters from Q4 2025 to Q3 2026.

Q3 2026 revenue of KRW 10.5 billion was down 22.9% year on year, and the operating loss widened to KRW 973 million. On the positive side, the company has KRW 41 billion in equity and a price-to-book ratio below 1x, along with past earnings recovery in 2023 and 2024.

On the negative side, the four-quarter controlling-shareholder net loss totaled KRW 2.21 billion, sales are concentrated in Korea, and OTC products have contributed little.

Whether the restructuring costs the company cited for the 2025 swing were temporary can be judged from the operating margin in the 2026 annual report and later quarters.

The next checkpoints are the FY2026 preliminary annual results, expected around early February 2027, and the 2026 annual business report, due by the end of March 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. comp.fnguide.com
  2. comp.fnguide.com
  3. k5.co.kr
  4. kr.investing.com
  5. m.news.nate.com
  6. news.nate.com
  7. edaily.co.kr
  8. bbn.kiwoom.com
  9. bosa.co.kr
  10. catch.co.kr
  11. medipharmhealth.co.kr
  12. eugenefn.com
  13. incruit.com
  14. kind.krx.co.kr
  15. jasoseol.com
  16. m.dailypharm.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis